Opinion|Videos|October 25, 2024
Impact of SC Daratumumab
Key Takeaways
- FDA approval of daratumumab and hyaluronidase-fihj with VRd offers new treatment options for transplant-eligible multiple myeloma patients, potentially improving outcomes.
- The combination therapy's approval signifies a shift towards more comprehensive and effective treatment regimens in newly diagnosed multiple myeloma.
Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With the new FDA approval of daratumumab and hyaluronidase-fihj in combination with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma, how does this impact treatment within this patient population?
- (Dr Adams) A recent pharmacy-led initiative showed that observation following subcutaneous administration of daratumumab may not be needed if the first injection is tolerated. How does this change patient monitoring procedures by the care team?
Advertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
5